Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

This study has been completed.
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Cancer and Leukemia Group B
Children's Oncology Group
Information provided by (Responsible Party):
Southwest Oncology Group Identifier:
First received: September 11, 2000
Last updated: March 5, 2015
Last verified: March 2015
Results First Received: August 20, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Melanoma (Skin)
Interventions: Biological: interleukin-2
Biological: filgrastim
Biological: interferon alfa
Drug: cisplatin
Drug: dacarbazine
Drug: vinblastine

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Interferon interferon alfa IV
Biochemotherapy cisplatin, dacarbazine, interleukin-2, interferon alfa SC, filgrastim

Participant Flow:   Overall Study
    Interferon   Biochemotherapy
STARTED   212   220 
Eligible   203   200 
Eligible and Treated   203   199 
COMPLETED   87   159 
NOT COMPLETED   125   61 
Adverse Event                39                29 
Death                1                0 
Refusal unrelated to adverse effects                8                4 
Progression/relapse                54                2 
Not eligible                9                20 
Withdrawal by Subject                0                1 
Not protocol specified                14                5 

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Interferon interferon alfa
Biochemotherapy cisplatin, dacarbazine, interleukin-2, interferon alfa SC, filgrastim
Total Total of all reporting groups

Baseline Measures
    Interferon   Biochemotherapy   Total
Overall Participants 
[units: participants]
 203   199   402 
[units: years]
Median (Full Range)
 (12 to 73) 
 (10 to 74) 
 (10 to 74) 
[units: participants]
Female   62   58   120 
Male   141   141   282 
Region of Enrollment 
[units: participants]
United States   203   199   402 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   5-year Overall Survival   [ Time Frame: Every three months for a year, every six months for years 2-5, annual for years 5-10 ]

2.  Primary:   5-year Relapse-Free Survival   [ Time Frame: Every three months for the first year, every 6 months for years 2-5, annually for years 6-10 ]

3.  Secondary:   Toxicity   [ Time Frame: While on treatment, patients on the HDIFN arm were assessed weekly for the 1st month, then every 2 weeks for the 2nd month, then every 3 months therafter; patients on the biochemo arm were assessed daily for the 1st 5 days, then weekly thereafter. ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: SWOG Melanoma Statistician
Organization: SWOG statistical office
phone: 206-667-4408

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Southwest Oncology Group Identifier: NCT00006237     History of Changes
Obsolete Identifiers: NCT00546416
Other Study ID Numbers: S0008
U10CA032102 ( US NIH Grant/Contract Award Number )
S0008 ( Other Identifier: SWOG )
CALGB-500002 ( Other Identifier: CALGB )
ECOG-S0008 ( Other Identifier: ECOG )
COG-S0008 ( Other Identifier: COG )
Study First Received: September 11, 2000
Results First Received: August 20, 2012
Last Updated: March 5, 2015
Health Authority: United States: Federal Government
United States: Food and Drug Administration